Sure, sure. And maybe the way I could start that, Kevin, start the conversation in Q3 and Q4, so maybe just talk a little bit about the half, sort of what's implied in terms of guide for the half, just to give you some perspective. So To the midpoint of our revenue guidance, the $18,050,000,000 that would imply a revenue Increased on a year over year basis of $500,000,000 Now importantly, when you look at that, It includes our biological acquisitions. So there's about 300 of that $500,000,000 that's coming about as a result of the acquisitions. On the EBITDA, what's implied, our actual last year for the second half Was $466,000,000 This year round numbers, it's about $600,000,000 And again, very importantly, The biologicals acquisition represents about $70,000,000 If you look at that 90,000,000 Number that we've given you is a full year guide for biologicals contribution to EBITDA, dollars 20,000,000 roughly in the first half, $70,000,000 in the second half.